Author

G. Gulden

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

B. Sert· 2 shared C. Tastan· 2 shared E. Ovali· 2 shared N. Tarhan· 2 shared T. Teymur· 2 shared Y. Ay· 2 shared E. Guzenge· 1 shared H. E. Erdil· 1 shared

Activity by Year

2023-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 42 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

B. Sert

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Phytohemagglutinin-Activated CAR-T Cells: Prolonged Persistence and Enhanced Anti-Tumor Response in CD19-Specific Acute Lymphoblastic Leukemia

B. Sert, G. Gulden, T. Teymur, Y. Ay, R. D. Turan, O. M. Unaldi, E. Guzenge, H. E. Erdil, S. Isik, P. Oz, I. Bozkurt, T. Arpaci, O. Kamali, E. Ovali, N. Tarhan, C. Tastan

This paper develops and tests two CD19-specific CAR-T cell designs, showing that PHA-activated CAR19BB-T cells provide prolonged persistence and enhanced anti-tumor effects in preclinical models of ALL.

bioRxiv · Jul 15, 2023 · PreprintImmunology

CAR-T Cells with Phytohemagglutinin (PHA) Provide Anti-Cancer Capacity with Better Proliferation, Rejuvenated Effector Memory, and Reduced Exhausted T Cell Frequencies

G. Gulden, B. Sert, T. Teymur, Y. Ay, N. N. Tiryaki, E. Ovali, N. Tarhan, C. Tastan

This study shows that using Phytohemagglutinin (PHA) to activate CAR-T cells increases their proliferation, memory T cell populations, and anti-cancer efficacy compared to aCD3/aCD28 activation.

Vaccines · Jan 31, 2023Peer-reviewedCancer Biology